Get the Stockscreener App
0.022
0.00%
0.00
Syros Pharmaceuticals Inc stock is traded at $0.022, with a volume of 6,639.
It is up +0.00% in the last 24 hours and down -79.82% over the past month.
See More
Previous Close:
$0.022
Open:
$0.022
24h Volume:
6,639
Relative Volume:
1.94
Market Cap:
$N/A
Revenue:
$9.94M
Net Income/Loss:
$-144.49M
P/E Ratio:
-0.00436
EPS:
-5.05
Net Cash Flow:
$-103.90M
1W Performance:
+0.00%
1M Performance:
-79.82%
6M Performance:
-98.42%
1Y Performance:
-99.50%
1-Day Range:
$0.022
$0.0227
1-Week Range:
$0.022
$0.0227
52-Week Range:
$0.022
$0.0282
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare SYRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.0227 | 0 | 9.94M | -144.49M | -103.90M | -5.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.48 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
514.15 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.19 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.99 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
258.17 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
Levi & Korsinsky Reminds Syros Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities LawsSYRS - ACCESS Newswire
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Rating of “Hold” from Analysts - Defense World
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
SYRS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Syros Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - MSN
Rege Nephro Acquires Assets from Syros Pharmaceuticals (SYRS) - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS) | SYRS Stock News - GuruFocus
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Phar - GuruFocus
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - digitalmore.co
Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Brokerages - Defense World
Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday - Defense World
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India
Analyze Syros Pharmaceuticals Inc (NASDAQ: SYRS) Before Investing. - stocksregister.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Syros Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Syros Pharmaceuticals settles debt with Oxford Finance By Investing.com - Investing.com South Africa
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com India
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga
Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025 - Marketscreener.com
Syros Pharmaceuticals, Inc. Announces Management Changes -February 28, 2025 at 04:15 pm EST - Marketscreener.com
Stocks to Watch: Toro, Syros Pharmaceuticals - MarketWatch
Syros to delist from Nasdaq, deregister from SEC - MSN
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
1.05%
Cap:
|
Volume (24h):